A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride (Ra-223) in HER2^- hormone receptor⁺ breast cancer patients with bone metastases.

Authors

Robert E. Coleman

University of Sheffield, Weston Park Hospital, Sheffield, United Kingdom

Robert E. Coleman , Rui Li , Amrita G. Sawhney , Oana Petrenciuc , Hope S. Rugo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases.

First Author: Hope S. Rugo

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy (HT) ± radium-223 dichloride (Ra-223) in HER2^- hormone receptor⁺ breast cancer patients (pts) with bone metastases (mets).

First Author: Robert E. Coleman

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement.

First Author: Peter Schmid

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy.

First Author: Kevin Kalinsky